Cytokinetics, Inc.
576 articles with Cytokinetics, Inc.
-
Cytokinetics Reports Second Quarter 2022 Financial Results
8/4/2022
Cytokinetics, Incorporated reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million, or $0.86 per share.
-
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials
8/4/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced a new release of the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from Cytokinetics’ completed clinical trials in ALS including, BENEFIT-ALS.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 01, 2022
8/1/2022
Cytokinetics, Incorporated announced that on July 29, 2022 it granted stock options to purchase an aggregate of 88,200 shares of common stock to 11 new employees, whose employment commenced in July 2022, as a material inducement to their employment.
-
Cytokinetics to Announce Second Quarter Results on August 4, 2022
7/21/2022
Cytokinetics, Incorporated announced that it is scheduled to report second quarter results on August 4, 2022 at 4:00 PM Eastern Time.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 05, 2022
7/5/2022
Cytokinetics, Incorporated announced that on June 30, 2022 it granted stock options to purchase an aggregate of 180,450 shares of common stock to 19 new employees, whose employment commenced in June 2022, as a material inducement to their employment.
-
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
7/1/2022
Cytokinetics, Incorporated announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Cytokinetics Announces Proposed Convertible Senior Notes Offering - June 29, 2022
6/29/2022
Cytokinetics, Incorporated announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
6/24/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company that the previously announced meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the New Drug Application for omecamtiv mecarbil is currently scheduled for December 13, 2022.
-
Cytokinetics Provides Regulatory Update for Omecamtiv MecarbilRecent Company Submission in Response to FDA Request Extends PDUFA Date
6/17/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related to the company’s new drug application (NDA).
-
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALSManaged Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022
6/16/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of COURAGE-ALS OLE an open-label extension clinical study designed to assess the long-term safety and tolerability of reldesemtiv in people with amyotrophic lateral sclerosis (ALS).
-
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
6/13/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from a new analysis of REDWOOD-HCM at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions.
-
Cytokinetics Announces Additional Results From REDWOOD-HCM to Be Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
6/3/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from a new analysis from REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) relating to the effect of treatment with aficamten on measures of cardiac structure and function will be presented in a poster presentation at the American Society of Echocardiography (ASE) 33rd Annual Scientific Sessions.
-
Cytokinetics to Participate in Upcoming Investor Conferences - June 02, 2022
6/2/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
Cytokinetics, Incorporated announced that on May 31, 2022 it granted stock options to purchase an aggregate of 179,100 shares of common stock to 23 new employees, whose employment commenced in May 2022, as a material inducement to their employment.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Cytokinetics filed with the SEC reporting that the FDA planned to hold an advisory committee meeting to review its New Drug Application (NDA) for omecamtiv mecarbil.
-
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
5/17/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26, 2022.
-
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv MecarbilFDA Plans to Convene Advisory Committee Meeting
5/17/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil.
-
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
5/16/2022
Cytokinetics, Incorporated announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May 21, 2022 – May 24, 2022.
-
Cytokinetics Reports First Quarter 2022 Financial Results
5/4/2022
Cytokinetics, Incorporated reported financial results for the first quarter of 2022.